8-Hydroxy-2′-deoxyguanosine (8-OHdG) as a possible marker of arsenic poisoning: a clinical case study on the relationship between concentrations of 8-OHdG and each arsenic compound in urine of an acute promyelocytic leukemia patient being treated with arsenic trioxide

• Published in: Forensic toxicology Vol. 27; no. 1; pp. 41 - 44
• Main Authors: Fujihara, Junko, Agusa, Tetsuro, Tanaka, Junko, Fujii, Yoshimi, Moritani, Tamami, Hasegawa, Masanori, Iwata, Hisato, Tanabe, Shinsuke, Takeshita, Haruo
• Format: Journal Article
• Language: English
• Published: Japan Springer Japan 01.02.2009
• Subjects: Case Report; Forensic Medicine; Forensic Science; Medical Law; Medicinal Chemistry; Medicine; Medicine & Public Health; Pharmacology/Toxicology; Promyelocytic leukemia; Arsenic trioxide; Monomethylarsonic acid; Dimethylarsinic acid; 8-OHdG
• ISSN: 1860-8965; 1860-8973
• DOI: 10.1007/s11419-008-0062-x

Arsenic trioxide (ATO) is an effective therapeutic agent for acute promyelocytic leukemia (APL). In the present study, the concentrations of 8-hydroxy-2′-deoxyguanosine (8-OHdG) and arsenic compounds [(dimethylarsinic acid (DMA), monomethylarsonic acid (MMA), As(V), and As(III)] in urine of an APL patient were determined during ATO treatment. The concentrations of 8-OHdG, DMA, and MMA were increased, especially during the fi rst consolidation therapy. Signifi cant positive correlations were observed between concentrations of 8-OHdG and DMA, between concentrations of 8-OHdG and MMA, and between concentrations of 8-OHdG and the sum of arsenic compounds. The present study supports the idea that urinary 8-OHdG can be a marker for arsenic poisoning, when it is detected together with DMA and MMA. In addition, this study is the fi rst to show the relationship between 8-OHdG and levels of arsenic compounds in urine of an APL patient being treated with ATO.